<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00915772</url>
  </required_header>
  <id_info>
    <org_study_id>1218.52</org_study_id>
    <secondary_id>2008-008494-59</secondary_id>
    <nct_id>NCT00915772</nct_id>
  </id_info>
  <brief_title>Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid</brief_title>
  <official_title>Extension Study Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid Versus Metformin 1000 mg Bid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      A phase III randomised, double-blind parallel group extension study to investigate the
      efficacy and safety of twice daily administration of the free combination of linagliptin 2.5
      mg + metformin 500 mg or of linagliptin 2.5 mg + metformin 1000 mg versus monotherapy with
      metformin 1000 mg twice daily over 54 weeks in type 2 diabetic patients previously completing
      the double-blind part of study 1218.46
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Patients With Adverse Events (AEs)</measure>
    <time_frame>54 weeks</time_frame>
    <description>This includes any AEs detected during routine physical examination and electrocardiogram (ECG) procedures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline at Week 54 in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)</measure>
    <time_frame>54 weeks</time_frame>
    <description>Baseline is defined as Visit 1 of 1218.52.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline at Week 54 in Pulse Rate</measure>
    <time_frame>54 weeks</time_frame>
    <description>Baseline is defined as Visit 1 of 1218.52.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Patients With Possibly Clinically Significant Abnormal Laboratory Parameters: Haematology</measure>
    <time_frame>54 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Possibly Clinically Significant Abnormal Laboratory Parameters: Clinical Chemistry</measure>
    <time_frame>54 weeks</time_frame>
    <description>ULN means upper limit of normal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Relevant Drug-related Abnormal Findings in Physical Examination and ECG as Reported as AE</measure>
    <time_frame>Baseline and drug stop (up to 54 weeks) + 7 days</time_frame>
    <description>Frequency of patients with adverse events by treatment, primary system organ class and preferred term</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c From Baseline Over Time</measure>
    <time_frame>54 weeks</time_frame>
    <description>HbA1c is measured as a percentage. Thus, this change from baseline reflects the visit HbA1c percent minus the baseline HbA1c percent. Baseline is defined as visit 1 of 1218.52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With HbA1c &lt;7.0% After 54 Weeks</measure>
    <time_frame>54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With HbA1c &lt;6.5% Over Time</measure>
    <time_frame>54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With HbA1c of at Least &lt;0.5% Over Time</measure>
    <time_frame>54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FPG From Baseline Over Time</measure>
    <time_frame>54 weeks</time_frame>
    <description>Baseline is defined as visit 1 of 1218.52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Rescue Therapy</measure>
    <time_frame>54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c From Baseline Over Time</measure>
    <time_frame>78 weeks</time_frame>
    <description>HbA1c is measured as a percentage. Thus, this change from baseline reflects the visit HbA1c percent minus the baseline HbA1c percent. Baseline is defined as visit 3 from study 1218.46 (NCT00915772).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">567</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Linagliptin + metformin bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin low dose + metformin 500 mg, bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linagliptin+ metformin bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin low dose + metformin 1000 mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin bid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 1000 mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin + metformin</intervention_name>
    <description>Linagliptin tablet low dose + metformin tablet 500 mg bid</description>
    <arm_group_label>Linagliptin + metformin bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin+metformin</intervention_name>
    <description>Linagliptin low dose tablet + metformin 1000 mg tablet bid</description>
    <arm_group_label>Linagliptin+ metformin bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 1000 mg tablet bid</description>
    <arm_group_label>Metformin bid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Signed and dated written informed consent, at the latest by the date of Visit 1

          -  Patients completing the entire treatment period of the double-blind study 1218.46, who
             are not treated with rescue medication (Visit 7)

        Exclusion criteria:

          -  Patients who meet one or more of the withdrawal criteria of the treatment period of
             the previous study 1218.46

          -  Pre-menopausal women (last menstruation equal or less than 1 year prior to signing
             informed consent) who:

          -  are nursing or pregnant,

          -  or are of child-bearing potential and are not practicing an acceptable method of birth
             control, or do not plan to continue using this method throughout the study and do not
             agree to submit to periodic pregnancy testing during participation in the trial.
             Acceptable methods of birth control include transdermal patch, intra uterine
             devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, sexual
             abstinence and vasectomised partner and in addition for male partners a barrier
             method, such as the use of condom with spermicide. No exception will be made.

          -  Alcohol abuse within the 3 months prior to informed consent that would interfere with
             study participation

          -  Drug abuse that in the opinion of the investigator would interfere with trial
             participation

          -  Any other clinical condition which, in the opinion of the investigator, would not
             allow safe completion of the protocol and safe administration of the study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1218.52.11005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.11003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.11002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Red Deer</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.11006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.11008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.11004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.11007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.11010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.38502 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Karlovac</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.38503 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krapinske Toplice</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.38504 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osijek</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.38505 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rijeka</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.38501 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sisak</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.37202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pärnu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.37201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallin</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.37203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallin</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.3303D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aire sur l'Aadour</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.3308B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bischheim</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.3305A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bourges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.3304F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bousse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.3308C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gambsheim</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grenoble cédex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.3305B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guerigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.3304A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jarny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.3302D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Riche</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.9999 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Riche</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.3307A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Seyne sur Mer</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.3307E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Seyne sur Mer</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.3305G Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lury</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.3303A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mont de Marsan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.3308F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mundolsheim</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.3305E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nevers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.3306A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ortez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.3306C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orthez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.3302E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Savonnières</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.3303B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Martin d'Oney</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.3308A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.3308D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.3308E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.3307D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.3302A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bad Dürrheim-Sunthausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Schauenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.91009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aurangabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.91001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.91004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.91012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.91011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bhopal</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.91003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.91020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.91018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyderadad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.91008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.91002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Karnataka</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.91007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Karnataka</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.91019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madurai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.91013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.91015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.91014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagpru</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.91016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>P.O.Trivandrum</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.91010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.91006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>West Bengal</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.37001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.37004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.37003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.52006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.52002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cuernavaca</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.52004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.52007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.52008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.52010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tijuana</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.52009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Veracruz</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.31004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>'s Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.31005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>'s Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Almere</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.31002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beek en Donk</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.31010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.31013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.31014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Velp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.31015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zoetermeer</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.40001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alba Iulia</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.40005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Galati</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.40003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.40002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ploiesti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.40004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Satu Mare</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.70001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.70002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.70003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.70004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.70006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.70005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.70007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.46002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.46003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Malmo</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.46005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.2162A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bab Saâdoun Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.2162B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bab Sâadoun Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.9992 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bab Sâadoun Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.2161A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.2161B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.2163A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.2163B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.9991 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.9993 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.38001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.38005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lvov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.38004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.52.38006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Sweden</country>
    <country>Tunisia</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2009</study_first_submitted>
  <study_first_submitted_qc>June 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2009</study_first_posted>
  <results_first_submitted>June 13, 2012</results_first_submitted>
  <results_first_submitted_qc>June 13, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 18, 2012</results_first_posted>
  <last_update_submitted>April 29, 2014</last_update_submitted>
  <last_update_submitted_qc>April 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>In this study, 567 patients were entered and randomised, but only 566 were treated. Therefore the treated set (TS) comprises 566 patients.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>M1000</title>
          <description>Metformin 1000mg monotherapy twice daily</description>
        </group>
        <group group_id="P2">
          <title>L2.5+M500</title>
          <description>Linagliptin 2.5mg and metformin 500mg twice daily</description>
        </group>
        <group group_id="P3">
          <title>L2.5+M1000</title>
          <description>Linagliptin 2.5mg and metformin 1000mg twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="170"/>
                <participants group_id="P2" count="225"/>
                <participants group_id="P3" count="171"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
                <participants group_id="P2" count="179"/>
                <participants group_id="P3" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused to continue trial medication</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Any other reason</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>M1000</title>
          <description>Metformin 1000mg monotherapy twice daily</description>
        </group>
        <group group_id="B2">
          <title>L2.5+M500</title>
          <description>Linagliptin 2.5mg and metformin 500mg twice daily</description>
        </group>
        <group group_id="B3">
          <title>L2.5+M1000</title>
          <description>Linagliptin 2.5mg and metformin 1000mg twice daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="170"/>
            <count group_id="B2" value="225"/>
            <count group_id="B3" value="171"/>
            <count group_id="B4" value="566"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.6" spread="10.7"/>
                    <measurement group_id="B2" value="56.0" spread="10.7"/>
                    <measurement group_id="B3" value="55.7" spread="10.8"/>
                    <measurement group_id="B4" value="55.8" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI) continuous</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.33" spread="5.22"/>
                    <measurement group_id="B2" value="29.06" spread="4.95"/>
                    <measurement group_id="B3" value="28.64" spread="4.79"/>
                    <measurement group_id="B4" value="29.01" spread="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.09" spread="18.92"/>
                    <measurement group_id="B2" value="79.17" spread="18.75"/>
                    <measurement group_id="B3" value="78.62" spread="16.86"/>
                    <measurement group_id="B4" value="79.58" spread="18.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Glycosylated haemoglobin (HbA1c) at baseline</title>
          <description>Based upon non-missing data, n=559 (5:1:1 missing in each of the groups respectively)</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.48" spread="0.99"/>
                    <measurement group_id="B2" value="7.64" spread="1.04"/>
                    <measurement group_id="B3" value="7.35" spread="1.12"/>
                    <measurement group_id="B4" value="7.50" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting plasma glucose (FPG) at baseline</title>
          <description>Based upon non-missing data, n=544 (6:10:6 missing in each of the groups respectively)</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156.585" spread="39.194"/>
                    <measurement group_id="B2" value="167.088" spread="44.633"/>
                    <measurement group_id="B3" value="153.721" spread="37.128"/>
                    <measurement group_id="B4" value="159.868" spread="41.206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Patients With Adverse Events (AEs)</title>
        <description>This includes any AEs detected during routine physical examination and electrocardiogram (ECG) procedures.</description>
        <time_frame>54 weeks</time_frame>
        <population>Treated Set (TS): all screened patients who were documented to have taken at lease 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>M1000</title>
            <description>Metformin 1000mg monotherapy twice daily</description>
          </group>
          <group group_id="O2">
            <title>L2.5+M500</title>
            <description>Linagliptin 2.5mg and metformin 500mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>L2.5+M1000</title>
            <description>Linagliptin 2.5mg and metformin 1000mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Patients With Adverse Events (AEs)</title>
          <description>This includes any AEs detected during routine physical examination and electrocardiogram (ECG) procedures.</description>
          <population>Treated Set (TS): all screened patients who were documented to have taken at lease 1 dose of study drug.</population>
          <units>participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="225"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="149"/>
                    <measurement group_id="O3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with severe AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with withdrawal due to AEs (from AE page)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at Week 54 in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)</title>
        <description>Baseline is defined as Visit 1 of 1218.52.</description>
        <time_frame>54 weeks</time_frame>
        <population>TS and observed cases (OC)</population>
        <group_list>
          <group group_id="O1">
            <title>M1000</title>
            <description>Metformin 1000mg monotherapy twice daily</description>
          </group>
          <group group_id="O2">
            <title>L2.5+M500</title>
            <description>Linagliptin 2.5mg and metformin 500mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>L2.5+M1000</title>
            <description>Linagliptin 2.5mg and metformin 1000mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Week 54 in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)</title>
          <description>Baseline is defined as Visit 1 of 1218.52.</description>
          <population>TS and observed cases (OC)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="214"/>
                <count group_id="O3" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DBP change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="8.5"/>
                    <measurement group_id="O2" value="-0.1" spread="7.4"/>
                    <measurement group_id="O3" value="0.3" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="12.2"/>
                    <measurement group_id="O2" value="-0.2" spread="13.2"/>
                    <measurement group_id="O3" value="2.2" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at Week 54 in Pulse Rate</title>
        <description>Baseline is defined as Visit 1 of 1218.52.</description>
        <time_frame>54 weeks</time_frame>
        <population>TS and observed cases (OC)</population>
        <group_list>
          <group group_id="O1">
            <title>M1000</title>
            <description>Metformin 1000mg monotherapy twice daily</description>
          </group>
          <group group_id="O2">
            <title>L2.5+M500</title>
            <description>Linagliptin 2.5mg and metformin 500mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>L2.5+M1000</title>
            <description>Linagliptin 2.5mg and metformin 1000mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Week 54 in Pulse Rate</title>
          <description>Baseline is defined as Visit 1 of 1218.52.</description>
          <population>TS and observed cases (OC)</population>
          <units>beats per minute (bpm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="214"/>
                <count group_id="O3" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="7.7"/>
                    <measurement group_id="O2" value="0.6" spread="8.3"/>
                    <measurement group_id="O3" value="0.1" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Patients With Possibly Clinically Significant Abnormal Laboratory Parameters: Haematology</title>
        <time_frame>54 weeks</time_frame>
        <population>TS and observed cases (OC)</population>
        <group_list>
          <group group_id="O1">
            <title>M1000</title>
            <description>Metformin 1000mg monotherapy twice daily</description>
          </group>
          <group group_id="O2">
            <title>L2.5+M500</title>
            <description>Linagliptin 2.5mg and metformin 500mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>L2.5+M1000</title>
            <description>Linagliptin 2.5mg and metformin 1000mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Patients With Possibly Clinically Significant Abnormal Laboratory Parameters: Haematology</title>
          <population>TS and observed cases (OC)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="225"/>
                <count group_id="O3" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Haematocrit abnormality: &lt;=32%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoglobin abnormality:Female ≤9.5;Male ≤11.5g/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Blood Cells abnormality: &lt; 3* 10^12/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cells abnormal decrease: &lt; 3 * 10^9/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cells abnormal increase: &lt;20.1*10^9/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets abnormal decrease: &lt;= 75* 10^9/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets abnormal increase: &gt;= 700* 10^9/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Possibly Clinically Significant Abnormal Laboratory Parameters: Clinical Chemistry</title>
        <description>ULN means upper limit of normal</description>
        <time_frame>54 weeks</time_frame>
        <population>TS and observed cases (OC). In treatment group L2.5+M500, the number of patients analysed was 224 for lactate dehydrogenase abnormality and total bilirubin abnormality due to anailable data.</population>
        <group_list>
          <group group_id="O1">
            <title>M1000</title>
            <description>Metformin 1000mg monotherapy twice daily</description>
          </group>
          <group group_id="O2">
            <title>L2.5+M500</title>
            <description>Linagliptin 2.5mg and metformin 500mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>L2.5+M1000</title>
            <description>Linagliptin 2.5mg and metformin 1000mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Possibly Clinically Significant Abnormal Laboratory Parameters: Clinical Chemistry</title>
          <description>ULN means upper limit of normal</description>
          <population>TS and observed cases (OC). In treatment group L2.5+M500, the number of patients analysed was 224 for lactate dehydrogenase abnormality and total bilirubin abnormality due to anailable data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="225"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Eosinophils abnormality : ≥ 10%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium abnormal decrease: &lt; 130 mmol/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium abnormal increase: &gt; 160 mmol/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium abnormal decrease: &lt; 3 mmol/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium abnormal increase: &gt; 5.8 mmol/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium abnormal decrease: &lt; 1.8 mmol/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium abnormal increase: &gt; 3 mmol/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate abnormal decrease: &lt; 0.7 mmol/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate abnormal increase: &gt; 1.7 mmol/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Transaminase abnormality: ≥3xULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Transaminase (ALT) abnormality: &gt;= 3 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase abnormality: &gt;= 2 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>γ-glutamyl transpeptidase (GGT) increase:≥3ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate dehydrogenase abnormality: &gt;= 3 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine kinase abnormality: &gt;= 3 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase: &gt; 1.5 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total cholesterol abnormality: &gt; 300 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine abnormality: &gt;= 1.5 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin abnormality: &gt;= 2 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglyceride abnormality: &gt;300 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid abnormality:Female: &gt;10;Male: &gt;11 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin abnormality: &lt;2.5 g/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate abnormal decrease: &lt;21 mmol/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HbA1c From Baseline Over Time</title>
        <description>HbA1c is measured as a percentage. Thus, this change from baseline reflects the visit HbA1c percent minus the baseline HbA1c percent. Baseline is defined as visit 1 of 1218.52.</description>
        <time_frame>54 weeks</time_frame>
        <population>TS (OC) with non-missing data at visit</population>
        <group_list>
          <group group_id="O1">
            <title>M1000</title>
            <description>Metformin 1000mg monotherapy twice daily</description>
          </group>
          <group group_id="O2">
            <title>L2.5+M500</title>
            <description>Linagliptin 2.5mg and metformin 500mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>L2.5+M1000</title>
            <description>Linagliptin 2.5mg and metformin 1000mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c From Baseline Over Time</title>
          <description>HbA1c is measured as a percentage. Thus, this change from baseline reflects the visit HbA1c percent minus the baseline HbA1c percent. Baseline is defined as visit 1 of 1218.52.</description>
          <population>TS (OC) with non-missing data at visit</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="225"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in HbA1c to week 6 (n=157, 207 and 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.41"/>
                    <measurement group_id="O2" value="-0.24" spread="0.51"/>
                    <measurement group_id="O3" value="-0.26" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in HbA1c to week 18 (n=136, 184 and 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.56"/>
                    <measurement group_id="O2" value="-0.29" spread="0.79"/>
                    <measurement group_id="O3" value="-0.34" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in HbA1c to week 30 (n=121, 165 and 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.82"/>
                    <measurement group_id="O2" value="-0.41" spread="0.80"/>
                    <measurement group_id="O3" value="-0.36" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in HbA1c to week 42 (n=110, 152 and 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.78"/>
                    <measurement group_id="O2" value="-0.35" spread="0.80"/>
                    <measurement group_id="O3" value="-0.28" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in HbA1c to week 54 (n=98, 132 and 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.77"/>
                    <measurement group_id="O2" value="-0.28" spread="0.86"/>
                    <measurement group_id="O3" value="-0.24" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With HbA1c &lt;7.0% After 54 Weeks</title>
        <time_frame>54 weeks</time_frame>
        <population>Treated Set with non completers considered as failures (NCF)</population>
        <group_list>
          <group group_id="O1">
            <title>M1000</title>
            <description>Metformin 1000mg monotherapy twice daily</description>
          </group>
          <group group_id="O2">
            <title>L2.5+M500</title>
            <description>Linagliptin 2.5mg and metformin 500mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>L2.5+M1000</title>
            <description>Linagliptin 2.5mg and metformin 1000mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With HbA1c &lt;7.0% After 54 Weeks</title>
          <population>Treated Set with non completers considered as failures (NCF)</population>
          <units>participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="225"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="168"/>
                    <measurement group_id="O3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With HbA1c &lt;6.5% Over Time</title>
        <time_frame>54 weeks</time_frame>
        <population>Treated Set with non completers considered as failures (NCF)</population>
        <group_list>
          <group group_id="O1">
            <title>M1000</title>
            <description>Metformin 1000mg monotherapy twice daily</description>
          </group>
          <group group_id="O2">
            <title>L2.5+M500</title>
            <description>Linagliptin 2.5mg and metformin 500mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>L2.5+M1000</title>
            <description>Linagliptin 2.5mg and metformin 1000mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With HbA1c &lt;6.5% Over Time</title>
          <population>Treated Set with non completers considered as failures (NCF)</population>
          <units>participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="225"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="196"/>
                    <measurement group_id="O3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With HbA1c of at Least &lt;0.5% Over Time</title>
        <time_frame>54 weeks</time_frame>
        <population>Treated Set with non completers considered as failures (NCF)</population>
        <group_list>
          <group group_id="O1">
            <title>M1000</title>
            <description>Metformin 1000mg monotherapy twice daily</description>
          </group>
          <group group_id="O2">
            <title>L2.5+M500</title>
            <description>Linagliptin 2.5mg and metformin 500mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>L2.5+M1000</title>
            <description>Linagliptin 2.5mg and metformin 1000mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With HbA1c of at Least &lt;0.5% Over Time</title>
          <population>Treated Set with non completers considered as failures (NCF)</population>
          <units>participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="225"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="176"/>
                    <measurement group_id="O3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FPG From Baseline Over Time</title>
        <description>Baseline is defined as visit 1 of 1218.52.</description>
        <time_frame>54 weeks</time_frame>
        <population>TS (OC) with non-missing data at visit</population>
        <group_list>
          <group group_id="O1">
            <title>M1000</title>
            <description>Metformin 1000mg monotherapy twice daily</description>
          </group>
          <group group_id="O2">
            <title>L2.5+M500</title>
            <description>Linagliptin 2.5mg and metformin 500mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>L2.5+M1000</title>
            <description>Linagliptin 2.5mg and metformin 1000mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FPG From Baseline Over Time</title>
          <description>Baseline is defined as visit 1 of 1218.52.</description>
          <population>TS (OC) with non-missing data at visit</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="225"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in FPG to week 2 (n=158, 200 and 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.36" spread="27.86"/>
                    <measurement group_id="O2" value="-12.22" spread="28.70"/>
                    <measurement group_id="O3" value="-10.57" spread="28.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in FPG to week 6 (n=152, 189 and 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.18" spread="32.68"/>
                    <measurement group_id="O2" value="-13.28" spread="27.36"/>
                    <measurement group_id="O3" value="-13.46" spread="32.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in FPG to week 18 (n=133, 174 and 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.14" spread="43.18"/>
                    <measurement group_id="O2" value="-11.76" spread="33.10"/>
                    <measurement group_id="O3" value="-12.88" spread="33.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in FPG to week 30 (n=116, 156 and 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.22" spread="41.67"/>
                    <measurement group_id="O2" value="-13.49" spread="33.68"/>
                    <measurement group_id="O3" value="-13.90" spread="32.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in FPG to week 42 (n=103, 149 and 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.43" spread="30.48"/>
                    <measurement group_id="O2" value="-9.46" spread="33.61"/>
                    <measurement group_id="O3" value="-13.10" spread="34.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in FPG to week 54 (n=93, 132 and 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.02" spread="29.25"/>
                    <measurement group_id="O2" value="-7.24" spread="36.27"/>
                    <measurement group_id="O3" value="-9.82" spread="31.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Rescue Therapy</title>
        <time_frame>54 weeks</time_frame>
        <population>TS</population>
        <group_list>
          <group group_id="O1">
            <title>M1000</title>
            <description>Metformin 1000mg monotherapy twice daily</description>
          </group>
          <group group_id="O2">
            <title>L2.5+M500</title>
            <description>Linagliptin 2.5mg and metformin 500mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>L2.5+M1000</title>
            <description>Linagliptin 2.5mg and metformin 1000mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Rescue Therapy</title>
          <population>TS</population>
          <units>Number of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="225"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="163"/>
                    <measurement group_id="O3" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HbA1c From Baseline Over Time</title>
        <description>HbA1c is measured as a percentage. Thus, this change from baseline reflects the visit HbA1c percent minus the baseline HbA1c percent. Baseline is defined as visit 3 from study 1218.46 (NCT00915772).</description>
        <time_frame>78 weeks</time_frame>
        <population>Non-switcher set (OC) with non-missing data at visit. Only patients who continued on the same treatment in both studies are included</population>
        <group_list>
          <group group_id="O1">
            <title>M1000</title>
            <description>Metformin 1000mg monotherapy twice daily</description>
          </group>
          <group group_id="O2">
            <title>L2.5+M500</title>
            <description>Linagliptin 2.5mg and metformin 500mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>L2.5+M1000</title>
            <description>Linagliptin 2.5mg and metformin 1000mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c From Baseline Over Time</title>
          <description>HbA1c is measured as a percentage. Thus, this change from baseline reflects the visit HbA1c percent minus the baseline HbA1c percent. Baseline is defined as visit 3 from study 1218.46 (NCT00915772).</description>
          <population>Non-switcher set (OC) with non-missing data at visit. Only patients who continued on the same treatment in both studies are included</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in HbA1c to week 30 (n=102, 103 and 108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.19" spread="0.98"/>
                    <measurement group_id="O2" value="-1.34" spread="0.91"/>
                    <measurement group_id="O3" value="-1.74" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in HbA1c to week 42 (n=90, 92 and 95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.16" spread="0.98"/>
                    <measurement group_id="O2" value="-1.31" spread="0.99"/>
                    <measurement group_id="O3" value="-1.62" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in HbA1c to week 54 (n=81, 81 and 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.20" spread="1.14"/>
                    <measurement group_id="O2" value="-1.41" spread="1.03"/>
                    <measurement group_id="O3" value="-1.73" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in HbA1c to week 66 (n=74, 73 and 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.26" spread="1.02"/>
                    <measurement group_id="O2" value="-1.42" spread="0.93"/>
                    <measurement group_id="O3" value="-1.65" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in HbA1c to week 78 (n=66, 66 and 78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.25" spread="0.91"/>
                    <measurement group_id="O2" value="-1.32" spread="1.06"/>
                    <measurement group_id="O3" value="-1.63" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Relevant Drug-related Abnormal Findings in Physical Examination and ECG as Reported as AE</title>
        <description>Frequency of patients with adverse events by treatment, primary system organ class and preferred term</description>
        <time_frame>Baseline and drug stop (up to 54 weeks) + 7 days</time_frame>
        <population>Treated Set (TS)</population>
        <group_list>
          <group group_id="O1">
            <title>M1000</title>
            <description>Metformin 1000mg monotherapy twice daily</description>
          </group>
          <group group_id="O2">
            <title>L2.5+M500</title>
            <description>Linagliptin 2.5mg and metformin 500mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>L2.5+M1000</title>
            <description>Linagliptin 2.5mg and metformin 1000mg twice daily</description>
          </group>
          <group group_id="O4">
            <title>Post-treat</title>
            <description>7 days follow-up period</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relevant Drug-related Abnormal Findings in Physical Examination and ECG as Reported as AE</title>
          <description>Frequency of patients with adverse events by treatment, primary system organ class and preferred term</description>
          <population>Treated Set (TS)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="225"/>
                <count group_id="O3" value="171"/>
                <count group_id="O4" value="566"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cardiogenic shock</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supraventricular tachycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>54 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>M1000</title>
          <description>Metformin 1000 mg twice daily</description>
        </group>
        <group group_id="E2">
          <title>L2.5+M500</title>
          <description>Linagliptin 2.5 mg + Metformin 500 mg twice daily</description>
        </group>
        <group group_id="E3">
          <title>L2.5+M1000</title>
          <description>Linagliptin 2.5 mg + Metformin 1000 mg twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Holoprosencephaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Dacryocystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="77" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Glycosylated haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Other - Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

